An analysis of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Its evolvement in the U.S. political context, particularly Congress, and its social ramifications are reviewed.
Get full access to this article
View all access options for this article.
References
1.
OberlanderJ., The Political Life of Medicine, The University of Chicago Press, Chicago, Illinois, pp. 4–5, 2003.
2.
KennedyE., Dramatic Improvement or Death Spiral—Two Members of Congress Assess the Medicare Bill, The New England Journal of Medicine, 350(8), pp. 747–751, February 19, 2004.
3.
WalkerD., Medicare: Financial Challenges and Considerations for Reform, Testimony Before The Joint Economic Committee of the United States Congress, Washington, D.C., 26 pp., April 10, 2003.
4.
ReinhardtU., A Primer for Journalists on Medicare Reform Proposals, a paper prepared on March 28, 2003. Princeton, New Jersey, 32 pp.
5.
Congressional Quarterly Today, Washington, D.C., p. 7, February 3, 2004.
6.
Centers for Medicare and Medicaid, CMS Facts & Figures, February 26, 2004.
7.
ReinhardtU., Perspective: Does U.S. Tax Financed Health Care Really Incur Waste?Health Affairs, pp. 99–100, July/August 2002.
8.
FrancisT., Medicare Drug Law Helps Business, The Wall Street Journal, p. A-3, March 2, 2004.
9.
The Henry J. Kaiser Family Foundation, Selected Survey Findings on the New Medicare Rx Drug Law, February 26, 2004, Menlo Park, California.
